PMID- 37496817
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230728
IS  - 2397-9070 (Electronic)
IS  - 2397-9070 (Linking)
VI  - 7
IP  - 7
DP  - 2023 Jul
TI  - Factors associated with the response to atezolizumab/bevacizumab combination 
      therapy for hepatocellular carcinoma.
PG  - 476-481
LID - 10.1002/jgh3.12932 [doi]
AB  - BACKGROUND AND AIM: The purpose of this study was to analyze factors associated 
      with the overall survival (OS) of atezolizumab/bevacizumab combination therapy 
      for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients 
      with ineffective therapy and those who discontinued treatment owing to adverse 
      events (AEs). METHODS: This retrospective multicenter study involved 139 patients 
      with aHCC who received atezolizumab/bevacizumab combination therapy between 
      November 2020 and September 2022. RESULTS: The median duration of treatment was 
      136.5 days, and the median observation period was 316 days. The overall response 
      rate was 40%, and the disease control rate was 78% according to mRECIST criteria. 
      Grade >/=2 AEs occurred in 63 patients (43%) and led to treatment discontinuation 
      in 16 patients. Multivariate analysis revealed that treatment response and 
      occurrence of grade >/=2 AEs after therapy, as well as low level of 
      albumin-bilirubin (ALBI) grade and low level of des-gamma carboxy prothrombin 
      (DCP) before therapy, were extracted as factors that contributed to OS. Log-rank 
      tests with the Kaplan-Meier method showed significant differences in OS among 
      these factors. The OS of patients who discontinued owing to AEs was significantly 
      shorter than that of other patients. CONCLUSION: Not only factors before therapy 
      but also treatment response and the appearance of AEs are involved in OS for 
      atezolizumab/bevacizumab combination therapy. Although the development of AEs 
      also contributed to OS, appropriate management of AEs is important to avoid 
      discontinuing treatment with this combination.
CI  - (c) 2023 The Authors. JGH Open published by Journal of Gastroenterology and 
      Hepatology Foundation and John Wiley & Sons Australia, Ltd.
FAU - Yano, Yoshihiko
AU  - Yano Y
AUID- ORCID: 0000-0002-5177-7480
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Yamamoto, Atsushi
AU  - Yamamoto A
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Mimura, Takuya
AU  - Mimura T
AD  - Hyogo Prefectural Hyogo Cancer Center Akashi Japan.
FAU - Kushida, Saeko
AU  - Kushida S
AD  - Hyogo Prefectural Hyogo Cancer Center Akashi Japan.
FAU - Hirohata, Seiya
AU  - Hirohata S
AD  - Hyogo Prefectural Kakogawa Medical Center Kakogawa Japan.
FAU - Yoon, Seitetsu
AU  - Yoon S
AD  - Hyogo Prefectural Kakogawa Medical Center Kakogawa Japan.
FAU - Hirano, Hirotaka
AU  - Hirano H
AD  - Yodogawa Christian Hospital Osaka Japan.
FAU - Kim, Soo Ki
AU  - Kim SK
AD  - Kobe Asahi Hospital Kobe Japan.
FAU - Hatazawa, Yuri
AU  - Hatazawa Y
AD  - Konan Medical Center Kobe Japan.
FAU - Momose, Kenji
AU  - Momose K
AD  - Osaka Saiseikai Nakatsu Hospital Osaka Japan.
FAU - Hayashi, Hiroki
AU  - Hayashi H
AD  - Kitaharima Medical Center Ono Japan.
FAU - Kado, Takuo
AU  - Kado T
AD  - Akashi Medical Center Akashi Japan.
FAU - Nishi, Katsuhisa
AU  - Nishi K
AD  - Hyogo Prefectural Awaji Medical Center Sumoto Japan.
FAU - Tanaka, Hidenori
AU  - Tanaka H
AD  - Sanda City Hospital Sanda Japan.
FAU - Matsuura, Takanori
AU  - Matsuura T
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Yoshida, Ryutaro
AU  - Yoshida R
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Asaji, Naoki
AU  - Asaji N
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Yasutomi, Eiichiro
AU  - Yasutomi E
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Shiomi, Yuuki
AU  - Shiomi Y
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Minami, Akihiro
AU  - Minami A
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Komatsu, Shohei
AU  - Komatsu S
AD  - Division of Hepato-Biliary-Pancreatic Surgery Kobe University Graduate School of 
      Medicine Kobe Japan.
FAU - Fukumoto, Takumi
AU  - Fukumoto T
AD  - Division of Hepato-Biliary-Pancreatic Surgery Kobe University Graduate School of 
      Medicine Kobe Japan.
FAU - Ueda, Yoshihide
AU  - Ueda Y
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
FAU - Kodama, Yuzo
AU  - Kodama Y
AD  - Division of Gastroenterology Kobe University Graduate School of Medicine Kobe 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20230615
PL  - Australia
TA  - JGH Open
JT  - JGH open : an open access journal of gastroenterology and hepatology
JID - 101730833
PMC - PMC10366485
OTO - NOTNLM
OT  - adverse event
OT  - hepatocellular carcinoma
OT  - immune checkpoint inhibitor
EDAT- 2023/07/27 06:42
MHDA- 2023/07/27 06:43
PMCR- 2023/06/15
CRDT- 2023/07/27 04:09
PHST- 2023/03/05 00:00 [received]
PHST- 2023/04/26 00:00 [revised]
PHST- 2023/06/05 00:00 [accepted]
PHST- 2023/07/27 06:43 [medline]
PHST- 2023/07/27 06:42 [pubmed]
PHST- 2023/07/27 04:09 [entrez]
PHST- 2023/06/15 00:00 [pmc-release]
AID - JGH312932 [pii]
AID - 10.1002/jgh3.12932 [doi]
PST - epublish
SO  - JGH Open. 2023 Jun 15;7(7):476-481. doi: 10.1002/jgh3.12932. eCollection 2023 
      Jul.